Complete has entered into a definitive agreement by which a wholly-owned U.S. subsidiary of BGI-Shenzhen will acquire Complete via a tender offer to purchase all outstanding shares of common stock of Complete for $3.15 per share in cash, without interest.

This price represents approximately a 54% premium to the $2.04 closing price per share of Complete common stock on June 4, 2012, the last trading day prior to Complete’s announcement that it was undertaking an evaluation of strategic alternatives to secure the financial resources needed for continued commercialization of our technology.

The company is privately-owned and is headquartered in Shenzhen, China. BGI includes both non-profit genomic research institutes and sequencing application commercial units that provide comprehensive sequencing and bioinformatics services for medical, agricultural and environmental applications. BGI works with leading U.S. institutions including Pfizer, Johnson & Johnson, Amgen, Celgene, Harvard University, Yale University, and the Dana-Farber Cancer Institute.

BGI has established a proven track record of excellence, delivering results which have generated over 250 articles in top-tier journals, including Nature and Science.

There are a number of key steps required to bring the transaction to a close.

Under the terms of the definitive merger agreement, a wholly-owned U.S. subsidiary of BGI will commence a tender offer to purchase all of the outstanding shares of Complete common stock for $3.15 per share in cash, without interest, within seven business days and the tender offer will remain open for a minimum of 20 business days following the commencement.

The tender offer is conditioned upon the satisfaction of various conditions, including, at least a majority of the outstanding common stock of Complete (determined on a fully diluted basis) being tendered, the termination of any waiting period under the U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976, clearance by the Committee on Foreign Investment in the United States, and the approval of certain governmental authorities in the People’s Republic of China.

Putting BGI and Complete together makes good strategic sense. The combination of the two companies is expected to bring together complementary scientific and

technological expertise and R&D capabilities to better position the combined organization to compete in the broad genomic sequencing industry.

We expect to close in early 2013.

There are a number of key steps required to bring the transaction to a close. As discussed in detail above, these steps include the condition that a majority of the Complete shares are tendered into the tender offer, approval by regulatory agencies, and other customary closing conditions.

Prior to completion of the merger, Complete will operate as it does today as an independent company. Once the merger is consummated, Complete will become a key U.S. subsidiary of BGI, with the financial resources to move forward with continued development and commercialization of its whole human genome sequencing services. BGI intends to preserve and support Complete’s culture and maintain headquarters and operations here in Mountain View.

The transaction will put Complete’s proprietary whole human genome sequencing technology on a firm financial footing, and the company will be better able to meet the needs of its customers. Our mission and standards of service will not change, and the combined organization will be stronger.

BGI intends to preserve and support Complete’s culture. Many employees will be involved in transition planning with BGI over the next weeks and months, and we’ll make sure that all employees are kept informed about the process. In the meantime, please continue to work on what you have been doing. We have genomes to sequence, customers to support, and new products to develop.

Yes.

Absolutely. We will continue to offer the world’s most accurate service for sequencing whole human genomes.

Under the terms of the agreement with BGI, you will be paid the in-the-money value of all of your vested and unvested stock options that are outstanding at the closing of the merger. The in-the-money value is determined by multiplying the number of shares subject to your options (whether vested or unvested) by the product obtained by subtracting your exercise price from $3.15. If any stock options have no in-the-money spread or the spread is negative, the options will be cancelled without the payment of any consideration. You will be paid $3.15 for each of your RSUs held

at the closing. These payments will be made in cash when the transaction closes. You will receive more detailed information as we move closer to closing the transaction.

Yes, the current proposed transaction doesn’t change our policies. An employee subject to the closed window must continue to comply with Complete Genomics insider trading policies. Please review the Complete Genomics Insider Trading Policy.

You are free to tender your shares into the merger or if you hold onto them, following the merger you will receive $3.15 per share.

The current offering period will continue in effect until the end of the offering period at which time purchases will be made as usual. No additional offer periods will commence after that purchase. If the merger closes prior to the last day of the current offering period, then, instead of the treatment described above, the offering period will end immediately prior to the effective time of the merger, and the purchase will be made at that time. The ESPP will be terminated immediately following the purchase described in the preceding sentences. (See the preceding question and answer for information on the treatment of shares purchased under the ESPP.)

BGI has committed to maintain employees at a minimum of current salary or wages for a period of twelve months following the merger and with current benefits for at least six months following the merger.

Current plans for bonuses are not affected by the announced transaction and to the extent that the bonuses become payable, we will pay them in accordance with the terms of the existing plans.

None. Because of strict SEC rules on public comments during the tender process and provisions in our agreement with BGI, you may not make any public comments on the transaction. Please be especially careful not to make comments on the transaction on any website or blog or via any social medium such as Facebook or Twitter. Refer any media inquiries to Cliff Reid or Keith Raffel, who will connect with our PR agency, Waggener Edstrom.